NETANYA, Israel, Dec. 15, 2021 /PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other.
/PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced.
Nerivio® Wearable Migraine Therapeutic Now Eligible for Insurance Coverage through UpScript s Telemedicine Platform
USA - English
News provided by
Share this article
Share this article
MONTCLAIR, N.J., April 12, 2021 /PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-authorized Nerivio® prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage through the UpScript direct-to-patient telemedicine platform. It is our mission to make Nerivio accessible to everyone who experiences migraine episodes, said Theranica CEO Alon Ironi. We appreciate the efforts UpScript made to make Nerivio available and covered through its advanced telemedicine platform. People with migraine need rapid, affordable access to safe and effective therapies, and this is exactly what they can get using UpScript. This service connects any patient wi
Share this article
Share this article
MONTCLAIR, N.J., March 2, 2021 /PRNewswire/ Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital therapeutics such as Nerivio, said Ronen Jashek, co-founder and COO of Theranica. We are pleased to see that Nerivio patients are showing both adherence to the treatment program and an increased level of comfort with the device itself. 100,000 treatments hold significance to Theranica, as does our recent 33% growth in monthly active users, because these numbers demonstrate that Nerivio users consistently see the benefits of this prescribed therapy to their well-being.